Company Profile
Biogen Stock Price, News & Analysis
- Ticker:
- BIIB
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Why the stock is moving
BIIB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Biogen is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to central nervous system and specialty-disease opportunities. Investors watch the stock for pipeline refresh and the durability of its commercial mix.
Geographic Base and Sector Classification
Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Biogen is followed within the neuroscience universe for its exposure to specialty therapeutics and central nervous system catalysts.
Business Model Characteristics
Biogen combines commercial products with pipeline renewal, so investors focus on launch execution, data quality, and whether the next wave of programs can keep the franchise moving forward.
Position Within the Biotechnology Landscape
Compared with smaller clinical-stage peers, Biogen trades as a more mature neuroscience platform, where the market still cares deeply about catalyst timing and pipeline conversion.
Future catalysts
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.
Recent news
The five most recent feed items are shown below in reverse chronological order.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Biogen do?
Biogen is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to central nervous system and specialty-disease opportunities. Investors watch the stock for pipeline refresh and the durability of its commercial mix.
Where is Biogen based and where is the stock listed?
Biogen is listed on NASDAQ, Headquartered in Cambridge, Massachusetts and listed on NASDAQ, Biogen is followed within the neuroscience universe for its exposure to specialty therapeutics and central nervous system catalysts..
On which exchange is BIIB stock listed?
Biogen (BIIB) is associated with NASDAQ, United States, Biotechnology.
What is lecanemab?
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise.
Which conditions is Biogen targeting with lecanemab?
Biogen is associated with neuroscience based on its company overview and current catalyst commentary.
How does Biogen describe recent progress with lecanemab?
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise.
What is Biogen?
Biogen is a neuroscience-focused biopharmaceutical company with a commercial base and a pipeline tied to central nervous system and specialty-disease opportunities.
What should investors watch for with Biogen?
Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise.
What is Investors?
Investors watch the stock for pipeline refresh and the durability of its commercial mix.